sorivudine has been researched along with Hematologic-Diseases* in 1 studies
1 trial(s) available for sorivudine and Hematologic-Diseases
Article | Year |
---|---|
Clinical effect of BV-araU on varicella-zoster virus infection in immunocompromised patients with haematological malignancies.
We evaluated the treatment of varicella-zoster infection with BV-araU in immuno-compromised patients with haematological malignancies in a randomized controlled study. Comparison was made between doses of 150 and 30 mg/day. For ethical reasons there was no placebo group. The percentage of patients given a 'very effective' rating by both attending physicians and the Evaluation Committee was significantly higher in the 150 mg/day group (56.0%) compared to the 30 mg/day group (15.0%). There was no significant difference in efficacy rate ('very effective' plus 'effective') between the two groups. The incidence of side effects was low (7.8%), all were mild and disappeared on stopping treatment. These results suggest that BV-araU is clinically useful, especially at a dose of 150 mg/day in immunocompromised patients. Further comparative studies between BV-araU and acyclovir or vidarabine are indicated. Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antiviral Agents; Arabinofuranosyluracil; Chickenpox; Child; Hematologic Diseases; Herpesvirus 3, Human; Humans; Immune Tolerance; Middle Aged; Remission Induction | 1991 |